皮肤黑色素瘤（SKCM）的发生和进展与免疫细胞浸润肿瘤微环境（TME）密切相关。本研究使用多个在线数据库检查了 SKCM 中 SIGLEC9 的表达、预后和免疫相关性。 GEPIA2和Ualcan数据库的分析显示，SIGLEC9在SKCM中高表达，SIGLEC9高表达的患者总生存期（OS）有所改善。此外，SKCM患者中SIGLEC9突变率为5.41%，为观察到的最高。根据TIMER的数据，SIGLEC9的表达与巨噬细胞、中性粒细胞和B细胞、CD8  T细胞、CD4  T细胞和树突状细胞呈正相关。基于TCGA-SKCM数据，我们验证了SIGLEC9的高表达与SKCM患者的良好预后密切相关，包括总生存期、无进展间期和疾病特异性生存期。这种积极的预后可能是由于免疫细胞浸润到 TME 中。此外，我们对单细胞转录组数据的分析表明，SIGLEC9不仅在正常皮肤免疫微环境中发挥作用，而且在SKCM患者的免疫细胞亚群中高表达，调节对肿瘤的免疫反应。我们的研究结果表明，SIGLEC9 与 SKCM 预后之间的密切关联主要是由其对肿瘤免疫微环境的影响介导的。© 2024。作者。

The occurrence and progression of skin cutaneous melanoma (SKCM) is strongly associated with immune cells infiltrating the tumor microenvironment (TME). This study examined the expression, prognosis, and immune relevance of SIGLEC9 in SKCM using multiple online databases. Analysis of the GEPIA2 and Ualcan databases revealed that SIGLEC9 is highly expressed in SKCM, and patients with high SIGLEC9 expression had improved overall survival (OS). Furthermore, the mutation rate of SIGLEC9 in SKCM patients was found to be 5.41%, the highest observed. The expression of SIGLEC9 was positively correlated with macrophages, neutrophils and B cells, CD8 + T cells, CD4 + T cells, and dendritic cells, according to TIMER. Based on TCGA-SKCM data, we verified that high SIGLEC9 expression is closely associated with a good prognosis for SKCM patients, including overall survival, progression-free interval, and disease-specific survival. This positive prognosis could be due to the infiltration of immune cells into the TME. Additionally, our analysis of single-cell transcriptome data revealed that SIGLEC9 not only played a role in the normal skin immune microenvironment, but is also highly expressed in immune cell subpopulations of SKCM patients, regulating the immune response to tumors. Our findings suggest that the close association between SIGLEC9 and SKCM prognosis is primarily mediated by its effect on the tumor immune microenvironment.© 2024. The Author(s).